Nachrichten zur Bristol-Myers Squibb Co Aktie

Bristol Myers Squibb: Aggressive M&A, A Riskier Strategy To Fix The Growth Challenge

…

NASDAQ-Titel Karuna Therapeutics-Aktie +47 %: Bristol-Myers Squibb will Karuna in Milliardendeal übernehmen - Bristol-Myers-Aktie in Grün

Die Transaktion habe einen Wert von 14 Milliarden US-Dollar (knapp 12,8 Mrd Euro), teilte das Unternehmen am Freitag in New…

Bristol Myers Squibb buys neurological drug developer Karuna Therapeutics in $14B deal

Shares of biopharmaceutical company Karuna Therapeutics skyrocketed more than 47% Friday morning after giant Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM,...…

Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal

Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.…

Bristol-Myers Squibb: Übernahme von Karuna Therapeutics für 14 Milliarden Dollar

Kurz vor Weihnachten gab Bristol-Myers Squibb die Übernahme von Karuna Therapeutics bekannt - ein Cash-Deal mit einem Volumen von 14…

NASDAQ-Titel Karuna Therapeutics-Aktie +47 %: Bristol-Myers Squibb will Karuna in Milliardendeal übernehmen - Bristol-Myers-Aktie tiefer

Die Transaktion habe einen Wert von 14 Milliarden US-Dollar (knapp 12,8 Mrd Euro), teilte das Unternehmen am Freitag in New…

Wall-Street-Ausblick: Ruhiger Wochenausklang zeichnet sich ab

Nike und Bristol-Meyers Squibb im Fokus…

Bristol-Myers Squibb auf Einkaufstour! Aktienanalyse

Kulmbach (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von "Der Aktionär": Michel Doepke vom Anlegermagazin "Der Aktionär" nimmt in einer aktuellen Aktienanalyse die Bristol-Myers…

5 Things to Know Before The Stock Market Opens

Pharmaceutical giant Bristol Myers Squibb is buying Karuna Therapeutics for $14 billion to expand its psychiatric drugs portfolio and Nike…

Karuna Therapeutics soars after $14 billion takeover by Bristol Myers

Bristol Myers, in its second major takeover of the year, will buy the schizophrenia and Alzheimers drugmaker Karuna Therapeutics for…

Übernahme-Hammer vor Weihnachten: Bristol-Myers Squibb mit Milliarden-Deal

Das Übernahmekarussell im Biotech-Sektor dreht sich weiter. Am letzten Handelstag vor Weihnachten wird die Übernahme von Karuna Therapeutics durch Bristol-Myers…

Übernahme-Hammer vor Weihnachten: Bristol-Myers Squibb mit Milliarden-Deal

Das Übernahmekarussell im Biotech-Sektor dreht sich weiter. Am letzten Handelstag vor Weihnachten wird die Übernahme von Karuna Therapeutics durch Bristol-Myers…

Milliardendeal: Bristol-Myers will Biopharmaunternehmen Karuna kaufen

NEW YORK (dpa-AFX) - Der US-Pharmakonzern Bristol-Myers Squibb will seinen Konkurrenten Karuna Therapeutics übernehmen. Die…

Bristol Myers to buy Karuna Therapeutics for $14 billion

Bristol Myers Squib agreed to buy Karuna Therapeutics for $14 billion on Friday, gaining a promising experimental schizophrenia drug.…

Bristol-Myers Squibb to acquire Karuna for $14 billion

Bristol-Myers Squibb to acquire Karuna for $14 billion - WSJ…

The Zacks Analyst Blog Highlights Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar

Microsoft, Booking Holdings, Bristol-Myers Squibb, Equifax hand First Solar are included in this Analyst Blog.…

Bristol Myers Squibb: This Dividend Contender Is A Steal Right Now

…

Better Dividend Stock: Bristol Myers Squibb or Merck?

These two pharma stocks have sizable dividend yields. Which is the better buy right now?…

Better Dividend Stock: Bristol Myers Squibb or Merck? @themotleyfool #stocks $BMY $MRK $^GSPC

These two pharma stocks have sizable dividend yields. Which is the better buy right now?…

Is Bristol Myers Squibb Stock a Buy Now?

The answer might depend on the kind of investor you are.…

Global Gene Therapy Market Size to Worth USD 49.21 Billion by 2032 | CAGR of 20.46%

The Global Gene Therapy Market Size was valued at USD 7.65 Billion in 2022 and the Worldwide Gene Therapy Market…

Bristol Myers Squibb Co. stock falls Thursday, underperforms market

Shares of Bristol Myers Squibb Co. slipped 0.75% to $51.47 Thursday, on what proved to be an all-around great trading…

Bristol-Myers Squibb: A Nice Deal For This Bargain Pharma Stock

…

ALLR: Stenoparib Clinical Update

By John Vandermosten, CFA NASDAQ:ALLR Early Results - Phase II Stenoparib Allarity Therapeutics, Inc. (NASDAQ:ALLR) provided an update to investors on its…

: Bristol Myers adds $3 billion to share buyback program to boost total to about $5 billion

Bristol Myers Squibb Co. BMY announced an additional $3 billion share buyback program on Thursday, boosting the full authorization to…

: Bristol Myers Squibb raises dividend by 5.3%

Bristol Myers Squibb Co. BMY said late Wednesday that its board has declared a quarterly dividend of 60 cents a…

Multiple Myeloma Market revenue to surpass USD 71 Billion by 2035, says Research Nester

Major multiple myeloma market players include Amgen Inc., Johnson & Johnson, Takeda Pharmaceuticals Company Limited, Novartis AG, Sanofi, Teva Pharmaceuticals…

Global Melanoma Therapeutics Market Size To Worth USD 12.35 Billion By 2032 | CAGR of 9.4%

The Global Melanoma Therapeutics Market Size was valued at USD 5.03 Billion in 2022 and the Worldwide Melanoma Therapeutics Market…

Bristol Myers Squibb new CEO buys company shares

…

Bristol Myers Squibb CEO Chris Boerner Buys Up Stock

…

Fortunes Can Be Made With Bristol-Myers Squibb

Taking a closer look at one of the largest companies in the pharmaceutical industry…

[Latest] Global Organ Transplantation Market Size/Share Worth USD 21.5 Billion by 2032 at a 9.5% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global…

Non-Oncology Biologics and Biosimilars Market is Booming and Expected to Grow at a CAGR of 21.8% to 2031

Companies covered in this report are AbbVie Inc., Sanofi, Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La…

Avidity Biosciences leaps on Bristol-Myers research tie-up

Avidity Biosciences soared 35% in pre-market trading after announcing a global licensing and research collaboration with Bristol-Myers Squibb Co...…

Bristol-Myers Squibb Is A Great Buy, But These 5+% Yielding Bargains Are Better

…

: Avidity’s stock soars on news of expanded collaboration with Bristol Myers that includes potential to receive up to $2.2 billion in milestone payments

Avidity Biosciences Inc. RNA said Tuesday it’s expanding its cardiovascular collaboration with Bristol Myers Squibb Co. BMY in a deal…

Global Non-Hodgkin Lymphoma Therapeutics Market Size To Worth USD 16.64 Billion by 2032 | CAGR of 7.8%

The Global Non-Hodgkin Lymphoma Therapeutics Market Size was valued at USD 7.85 Billion in 2022. The Worldwide Non-Hodgkin Lymphoma Therapeutics…

Bristol-Myers Squibb: The Patent Expiry Challenge

…

Bristol Myers Squibb: A Bitter Pill But Still A Buy

…

Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study

Companies covered in this study are Novartis, AstraZeneca, Merck & Co., Inc, Bristol-Myers Squibb, Pfizer, Eli Lilly and Company, Gilead…

Bristol-Myers Squibb: A Tough But Cheap Spot

…

Bristol Myers (BMY), TSVT Cell Therapy Abecma Faces Setback

Bristol Myers Squibb (BMY) and 2seventy bio, Inc.s efforts to seek approval for the label expansion of Abecma for earlier…

Dow Jones, S&P 500, Nasdaq: US-Anleger kaufen weiter ein

Bei den Einzelwerten geben die Aktien von Bristol Myers Squibb zum Handelsstart um rund vier Prozent nach. Dabei spielt auch…

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application By Investing.com

Bristol Myers Squibb slumps as FDA convenes advisory panel for drug application…

Bristol-Meyers Squibb shares fall as FDA delays blood cancer therapy decision

Bristol-Myers Squibb Co (NYSE:BMY) shares fell almost 5% after the company announced that a Food and Drug Administration (FDA) decision…

Bristol-Myers Squibb: Bayer-Nachrichten sind ein schlechtes Omen - Aktienanalyse

London (www.aktiencheck.de) - Bristol-Myers Squibb-Aktienanalyse von Barclays: Die Analysten von Barclays stufen die Aktie von Bristol-Myers Squibb Company (ISIN: US1101221083, WKN:…

Stocks making the biggest premarket moves: Boeing, Bristol-Myers Squibb, Chegg, Krispy Kreme and more

These are the stocks posting the largest moves in the premarket.…

: Bristol Myers Squibb, 2seventy bio shares fall as FDA delays action on cancer treatment

Shares of Bristol Myers Squibb, 2seventy bio fell early Monday as FDA said it would miss a regulatory action date…

Biggest stock movers today: Bristol Myers Squibb, NuScale Power, Chegg and more

…

Bayer Stock Plunges, Bristol Myers Squibb Falls After Negative Drug-Trial Result

The week is off to an ugly start for some pharmaceutical investors. Bayer said it is halting a trial for asundexian,…